Rockefeller Capital Management
HRMY icon

Rockefeller Capital Management’s Harmony Biosciences HRMY Stock Holding History

Rockefeller Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$430K Sell
11,806
-255
-2% -$8.04K ﹤0.01% 2170
2026
Q1 		$338K Sell
12,061
-5,722
-32% -$188K ﹤0.01% 2194
2025
Q4 		$665K Buy
17,783
+4,148
+30% +$136K ﹤0.01% 1752
2025
Q3 		$376K Buy
+13,635
New +$470K ﹤0.01% 1910
2023
Q1 		– Sell
-3
Closed – – 2840
2022
Q4 		$0 Hold
3
– – ﹤0.01% 4015
2022
Q3 		$0 Sell
3
-63
-95% -$3.07K ﹤0.01% 4093
2022
Q2 		$3K Buy
+66
New +$2.97K ﹤0.01% 3649

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's HRMY Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Harmony Biosciences (HRMY) stake by 2.1% in Q2 2026, selling an estimated $8.04K and leaving 11,806 shares worth $430K. The position accounts for ﹤0.01% of the portfolio, ranked #2170.

Rockefeller Capital Management first reported a position in HRMY in Q2 2022 and has held it in 7 quarters since. The position peaked at $665K in Q4 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Rockefeller Capital Management held 11,806 shares of Harmony Biosciences worth $430K as of Q2 2026.
  • Rockefeller Capital Management sold 255 Harmony Biosciences shares in Q2 2026, an estimated $8.04K.
  • Harmony Biosciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2170 holding.
  • Rockefeller Capital Management first reported a position in Harmony Biosciences in Q2 2022 and has held it in 7 quarters since.
  • Rockefeller Capital Management's Harmony Biosciences position peaked at $665K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.